Company Overview and News

Week ahead in business and finance

Shopping centre owner Hammerson needs to woo investors to save itself from crashing out of the FTSE 100 in this week’s quarterly reshuffle.
Upvote Downvote

International Personal Finance (IPFPY) On Introduction To IFRS 9 - Slideshow

2017-11-17 seekingalpha
fThe following slide deck was published by International Personal Finance Plc ADR in conjunction with this event.
Upvote Downvote

Poland Is Cracking Down on Billions in Corporate Tax Dodges - Bloomberg

2017-11-10 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
Upvote Downvote

Director/PDMR Shareholding

2017-08-07 londonstockexchange
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
Upvote Downvote

Total Voting Rights

2017-08-01 londonstockexchange
In conformity with the Disclosure Guidance and Transparency Rules 5.6.1R the Company hereby notifies the market that as at 31 July 2017:
Upvote Downvote

Pound comes off highs against dollar ahead of UK GDP data

Read today's Macro View @shjfrench: - US consumer confidence , UK #GDP & mgages. Bonus: i/view w/ BTG CEO Dame Makin
Upvote Downvote

UPDATE 1-UK Stocks-Factors to watch on July 26

2017-07-26 reuters
July 26 (Reuters) - Britain's FTSE 100 index is seen opening up 2 points on Wednesday, according to financial bookmakers, with futures down 0.07 pct ahead of the cash market open.
Upvote Downvote

Half-year Report

2017-07-26 londonstockexchange
Group profit before tax of £43.0M, an increase of £10.0M including a positive FX benefit of £6.7M
Upvote Downvote

Sale of home credit business in Bulgaria

2017-06-28 londonstockexchange
International Personal Finance plc ("IPF") has completed the sale of its home credit business in Bulgaria to Easy Asset Management AD, a large home credit operator in that market.  The sale allows IPF to focus its resources on its larger home credit and rapidly-growing digital businesses where there is a strong demand for unsecured consumer lending.  The transaction is expected to result in an exceptional charge to the profit and loss account of around £5M.
Upvote Downvote

Publication of Suppl.Prospcts

2017-06-16 londonstockexchange
The following supplemental prospectus (the "Supplemental Prospectus") has been approved by the UK Listing Authority and is available for viewing:
Upvote Downvote

Final Results

2017-06-14 londonstockexchange
Seneca Global Income & Growth Trust plc ('SIGT' or 'the Company') generated a net asset value ('NAV') total return for the year of +19.6% which was materially better than the benchmark return of +3.5%, being 3-month LIBOR plus 3%.  SIGT's NAV performance over the year compared reasonably well with most of the comparator indices, whose returns were: FTSE All-Share Index +20.1%, FTSE All-World ex-UK Index +32.
Upvote Downvote

The Change Catalyst - Secrets to Successful and Sustainable Business Change

2017-06-12 prnewswire
LONDON, June 12, 2017 /PRNewswire/ -- Wiley and Change & Strategy International are proud to announce the publication of "The Change Catalyst: Secrets to Successful and Sustainable Change" by Campbell Macpherson. It is a new business book ideal for the times in which we live.
Upvote Downvote

Credit rating update

2017-06-08 londonstockexchange
International Personal Finance plc ("IPF") notes that Fitch has downgraded the long-term credit rating of IPF by one notch from BB+ to BB, with outlook negative. This was part of the scheduled annual review of the rating by Fitch.
Upvote Downvote

Total Voting Rights

2017-06-01 londonstockexchange
In conformity with the Disclosure Guidance and Transparency Rules 5.6.1R the Company hereby notifies the market that as at 31 May 2017:
Upvote Downvote

Half-year Report

2017-05-24 londonstockexchange
The objective of Standard Life Equity Income Trust plc is to provide shareholders with an above average income from their equity investment while also providing real growth in capital and income.
Upvote Downvote

Related Articles

GNCA: Genocea Biosciences Analysis and Research Report

11h - Asif

Overview Genocea Biosciences is a biopharmaceutical company that discovers and develops novel cancer vaccines. The company use its proprietary discovery platform, ATLAS, to recall a patient’s pre-existing CD4+ and CD8+ T cell immune responses to their tumor to identify antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses. The company believe that using ATLAS to identify antigens for inclusion in cancer vaccines could lead to more immunogenic and efficacious cancer vaccines. In September 2017, the company announced a strategic shift to immuno-oncology and a focus on the development of neoantigen cancer vaccines. Currently, all of its research programs and product candidates in active development are at the preclinical stage. The company's most advanced program is its preclinical immuno-oncology program, GEN-009, a neoantigen cancer vaccine. The GEN-009 program uses ATLAS to identify patient neoantigens, or newly formed anti...

AMZN:, Inc Analysis and Research Report

12h - Asif

Overview opened its virtual doors on the World Wide Web in July 1995. The company seek to be Earth’s most customer-centric company. Amazon is guided by four principles: customer obsession rather than competitor focus, passion for invention, commitment to operational excellence, and long-term thinking. In each of its segments, the company serve its primary customer sets, consisting of consumers, sellers, developers, enterprises, and content creators. In addition, the company provide services, such as advertising services and co-branded credit card agreements. Amazon has organized its operations into three segments: North America, International, and Amazon Web Services (“AWS”). These segments reflect the way the Company evaluates its business performance and manages its operations. Additional information on its operating segments and its net sales is contained in Item 8 of Part II, “Financial Statements and Supplementary Data—Note 11—Segment Information.” The compan...

LPCN: Lipocine Inc Analysis and Research Report

2018-04-23 - Asif

Overview Lipocine is a specialty pharmaceutical company focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. The company's proprietary delivery technologies are designed to improve patient compliance and safety through orally available treatment options. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Lipocine has a portfolio of proprietary product candidates designed to produce favorable pharmacokinetic (“PK”) characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. The company's lead product candidate, TLANDO™, is an oral testosterone replacement therapy (“TRT”) and is currently under review by the United States Food and Drug Administration (“FDA”) with a Prescription Drug User Fee Act (“...